vimarsana.com

Latest Breaking News On - Engitix ltd - Page 3 : vimarsana.com

Engitix Therapeutics appoints Dr Mike Burbridge as VP Oncology and Immuno-oncology

Engitix Ltd (‘Engitix’), a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours and with two significant partnerships based on its pioneering proprietary human extracellular matrix (ECM) drug discovery platform, today announced that it has appointed Dr Mike Burbridge, as Vice President, Oncology & Immuno-oncology. Dr Gino Van Heeke, Engitix’s CSO said “We are delighted to have attracted a scientist as high calibre as Mike, who has the experience and expertise to help push forward our internal therapeutic projects as well as our partnered programmes. His extensive knowledge will also be invaluable in supporting the company’s ambitious plans in oncology drug discovery and development.”

Nonalcoholic Steatohepatitis Drug Pipeline Analysis Review, 2020

Major Players: 95+ Key Companies   Prominent Players: 89bio Inc, ABIONYX Pharma SA, Abivax SA, Abliva AB, Acquist Therapeutics, AdAlta Ltd, Afimmune Biopharma Ltd, Akero Therapeutics Inc, Albireo Pharma Inc, Aldeyra Therapeutics Inc, Ascletis Pharma Inc, Zhejiang Doer Biologics Corp, Asdera LLC, Assembly Biosciences Inc, AstraZeneca Plc, Auransa Inc, Avaliv Therapeutics Inc, Avolynt Inc, ChemoCentryx Inc, ChemomAb Ltd, Dicerna Pharmaceuticals Inc, Dr. Falk Pharma GmbH, DURECT Corp, Eli Lilly and Co, Enanta Pharmaceuticals Inc EncuraGen Inc, Engitix Ltd, Hepion Pharmaceuticals Inc, Heprotech Inc, Hinova Pharmaceuticals Inc, HK inno.N Corp, HotSpot Therapeutics Inc, Ildong Pharmaceutical Co Ltd, Imago Pharmaceuticals Inc, ImmuneMed Inc, Immupharma Plc, Immuron Ltd, Indalo Therapeutics Inc, Inmune Bio Inc, Innovimmune Biotherapeutics Inc, Inorbit Therapeutics AB, Integral Molecular Inc, Intercept Pharmaceuticals Inc, INVENT Pharmaceuticals Inc, InventisBio Inc, Inventiva, LG Chem Ltd

Engitix Therapeutics to Relocate Headquarters to New Life Sciences Cluster, White City Place

Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of programmes in fibrosis and solid tumours and two significant partnerships based on its proprietary human extracellular matrix (ECM) platform, today announced that it is relocating its headquarters and operations to WestWorks, White City Place (WCP). The move follows announcements of high-profile collaboration agreements with Takeda Pharmaceuticals and Morphic Therapeutic, to leverage the benefits of Engitix’ human ECM-based discovery platform to improve the success rate of drug discovery and development. This acknowledgement from two major players in the industry underpins the Company’s expansion, which starts with it moving to the 8,000 square feet facility of bespoke office and laboratory space in WCP.

Engitix Ltd: Engitix Therapeutics to Relocate Headquarters to New Life Sciences Cluster, White City Place

Engitix Ltd: Engitix Therapeutics to Relocate Headquarters to New Life Sciences Cluster, White City Place Engitix Ltd ( Engitix ), a biotechnology company with a portfolio of programmes in fibrosis and solid tumours and two significant partnerships based on its proprietary human extracellular matrix (ECM) platform, today announced that it is relocating its headquarters and operations to WestWorks, White City Place (WCP). The move follows announcements of high-profile collaboration agreements with Takeda Pharmaceuticals and Morphic Therapeutic, to leverage the benefits of Engitix human ECM-based discovery platform to improve the success rate of drug discovery and development. This acknowledgement from two major players in the industry underpins the Company s expansion, which starts with it moving to the 8,000 square feet facility of bespoke office and laboratory space in WCP.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.